Schmallenberg Virus Treatment Market, By Treatment Type Antiviral Drugs, Anti-inflammatory Drugs, Analgesics, Vaccines, Others), By Animal Type (Cattle, Sheep, Goats, Others), By End User (Veterinary Hospitals and Clinics, Research Institutions, Veterinary Pharmacies and Drug Store and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
The global Schmallenberg virus treatment market is valued at US$ 110 million in 2023 and is expected to reach US$ 193.8 million by 2030, growing at a compound annual growth rate (CAGR) of 8.4% from 2023 to 2030.
Schmallenberg virus (SBV) is a viral disease that primarily affects ruminant animals, including cattle, sheep, and goats. The virus was first identified in Europe in 2011 and has since spread to different regions globally. However, there were no specific antiviral treatments or vaccines approved for Schmallenberg virus in animals at that time.
Treatment options for the Schmallenberg virus are mainly focused on supportive care and management of symptoms to improve the animals' overall health and minimize the impact of the disease. These included providing pain relief, anti-inflammatory medications, and ensuring proper nutrition and hydration. Preventive measures, such as vector control and vaccination strategies, were also essential in minimizing the spread of the virus.
North America is the second-largest region in the market, with a share of over 38.9% in 2022. The U.S. is the largest market in North America, followed by Canada. The demand for vaccines in North America is driven by the high number of livestock farms in the region.
Europe is the leading region in the Schmallenberg virus treatment market, accounting for a share of over 28.9% in 2022. This is due to the high prevalence of SBV in Europe, as well as the strong demand for vaccines from livestock farmers. The European Commission has approved two vaccines for SBV, and these are widely used in the region.
Asia Pacific is the third-largest region in the market, with a share of over 23.1% in 2022. China is the largest market in Asia Pacific, followed by India. The demand for vaccines in Asia Pacific is driven by the growing livestock population in the region.
Figure 1. Global Schmallenberg Virus Treatment Market Share (%), By Region, 2023
The Schmallenberg virus treatment market is witnessing consistent growth as a result of rising concerns surrounding the impact of the Schmallenberg virus on livestock, particularly cattle, sheep, and goats. The market is primarily driven by the demand for effective treatment options, vaccines, and supportive care strategies to manage and control Schmallenberg virus outbreaks. Preventive actions and treatment options are becoming more and more necessary as knowledge about the virus and its effects on cattle health grows. Stringent regulatory environments and varying disease prevalence by region further shape the market's dynamics.
Ongoing research and development efforts, as well as the introduction of innovative treatments, are crucial factors that will influence the market's trajectory in the coming years. With the market segmented across various parameters, companies are well-positioned to address specific niches and adapt their strategies to the unique demands of each segment.
Schmallenberg Virus Treatment Market Drivers:
Emerging Outbreaks: The occurrence of new outbreaks of Schmallenberg virus in different regions drives the need for effective treatment options. As the virus spreads to new areas and affects more livestock, there is an increasing demand for treatments to mitigate the impact of the disease on animal health and productivity.
Growing Awareness: With increased awareness of the Schmallenberg virus and its potential effects on ruminant populations, veterinarians, livestock farmers, and animal health authorities seek effective treatment strategies. As stakeholders become more knowledgeable about the virus, they are likely to actively seek and adopt available treatment options. For instance, a survey was launched by the Ruminant Health & Welfare Organization in March 2022, an animal health organization in the U.K., to understand the impact of the rise in Schmallenberg virus on 2022 lambing season, as studies reveal that UK flocks are predicted to be entering a phase of increased risk for Schmallenberg virus.
Research and Development: Ongoing research and development efforts by veterinary pharmaceutical companies and academic institutions play a vital role in driving the Schmallenberg virus treatment market. Continuous research aims to identify antiviral drugs, vaccines, and supportive care measures to improve animal health outcomes.
Supportive Measures: While there may not be specific antiviral treatments for Schmallenberg virus, supportive measures, such as pain relief and anti-inflammatory medications, can be beneficial in managing symptoms and improving the well-being of infected animals. The availability and utilization of such supportive care options contribute to the overall treatment market.
Vaccine Development: The development of effective vaccines against Schmallenberg virus presented a significant opportunity in the treatment market. Vaccines could provide long-term protection against the virus and help prevent new outbreaks, benefiting both animal health and the livestock industry.
Antiviral Drugs: The identification and development of antiviral drugs specific to Schmallenberg Virus offered potential opportunities to directly target and combat the virus in infected animals. Antiviral drugs could help reduce the severity of symptoms and aid in the recovery of affected livestock.
Supportive Care Solutions: As specific antiviral treatments are limited, there is an opportunity for the development and promotion of supportive care solutions. Providing pain relief, anti-inflammatory medications, and nutrition support could improve the well-being and overall health of infected animals.
Diagnostic Tools: Improved diagnostic tools and tests for Schmallenberg virus detection could enhance early detection and timely treatment. Rapid and accurate diagnosis would help prevent further spread and enable targeted treatment strategies.
Schmallenberg Virus Treatment Market Trends:
Research and Vaccine Development: There is a growing trend of research and development efforts focused on finding effective vaccines against the Schmallenberg virus. Researchers and pharmaceutical companies were exploring various vaccine technologies to develop vaccines that could provide protection to livestock against the virus.
Supportive Care Solutions: Due to the limited availability of specific antiviral drugs for Schmallenberg virus, supportive care solutions were gaining prominence. Veterinary practitioners were emphasizing the importance of supportive care to manage symptoms, reduce pain and inflammation, and improve the well-being of infected animals.
Zoonotic Concerns: The zoonotic potential of Schmallenberg virus, though rare, remained a concern for public health. This trend led to increased vigilance and monitoring of potential human cases, promoting a one-health approach to manage the virus and its impact on both animals and humans.
Early Detection and Surveillance: Early detection and surveillance of Schmallenberg virus cases were becoming crucial for disease management. There was an increasing focus on improving diagnostic tools and surveillance systems to detect outbreaks promptly and implement control measures effectively.
Schmallenberg Virus Treatment Market Restraints:
No Proper Treatment Options: As there is no proper treatment for the Schmallenberg virus it acts as a significant restraint. The absence of targeted treatments made it challenging to combat the virus directly, leading to a reliance on supportive care measures.
Complexity of Vaccine Development: Developing vaccines for emerging viral diseases like schmallenberg virus presented challenges. The virus belongs to the Bunyaviridae family, and creating effective vaccines against such viruses can be technically demanding and time-consuming.
Moreover, key players are focused on developing new vaccines for the Schmallenberg Virus Treatment is expected to drive the market growth over the forecast period.
Figure 2. Global Schmallenberg Virus Treatment Market Share (%), By Animal Type, 2023
Zoetis launched a new vaccine for SBV in Europe in 2015. The vaccine, called Zulvac SBV, is a new Schmallenberg vaccine licensed for use in cattle and sheep in two doses at a three week interval.
Acquisition and partnerships
In September 2022, Zoetis acquired Jurox, one of the providers of livestock and companion animal products. The acquisition of Jurox brings Zoetis a range of important products primed for greater global expansion and a valuable animal health portfolio, including Alfaxan, a leading anesthetic product for companion animals.
In September 2022, Merck Animal Health, one of the leading animal healthcare company, announced that it had signed a definitive agreement to acquire Vence, an innovator in virtual fencing for rotational grazing and livestock management.
Top companies in Schmallenberg Virus Treatment Market
Boehringer Ingelheim
Zoetis
MSD Animal Health (Merck Animal Health)
Elanco Animal Health
Ceva Santé Animale
Virbac
Bayer Animal Health
Vetoquinol
Huvepharma
IDT Biologika
Heska Corporation
Dechra Pharmaceuticals
Phibro Animal Health
Neogen Corporation
Definition: Schmallenberg virus treatment refers to the medical interventions and management strategies aimed at mitigating the impact of the Schmallenberg virus on ruminant animals, such as cattle, sheep, and goats. As there is no specific antiviral drug or approved vaccine for the virus, treatment primarily focuses on supportive care measures to alleviate symptoms.
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
The global Schmallenberg Virus Treatment Market size was valued at USD 110 million in 2023 and is expected to reach USD 193.8 million in 2030.
No proper treatment options, the complexity of vaccine development, and low economic incentives are key factors hampering market growth.
Emerging outbreaks, growing awareness, research and development efforts, and the availability of supportive measures are major factors driving market growth.
The leading animal type segment is cattle in the market
Major players in the market include Boehringer Ingelheim, Zoetis, MSD Animal Health (Merck Animal Health), Elanco Animal Health, Ceva Santé Animale, Virbac, Bayer Animal Health, Vetoquinol, Huvepharma, IDT Biologika, Heska Corporation, Dechra Pharmaceuticals, Phibro Animal Health and Neogen Corporation
North America is the leading region in the market.
U.S.: 
U.K. : 
India : 
